Sign up for a free trial and join thousands of other leading professionals. Click here to start!

Drug-Coated Heart Stents News

Home | Index > Health > Heart & Blood > Drug-Coated Heart Stents

TAKE THIS POLL
Regardless of your general preferences, which U.S. presidential candidate's Iraq policy do you support? (Jul. 15, 2008) John McCain's policy. Barack Obama's 's policy. Don't know.

Boston Scientific's Q2 income down 24 Jul 2008 03:31 GMT
... The company has reported net sales of $2.02 billion, ... ICD sales. Worldwide sales of the company's drug-eluting coronary stent systems for the second quarter of 2008 ...
Boston Scientific slumps on 2Q earnings report 22 Jul 2008 16:11 GMT
... in a 52-week range of $10.76 to $15.31. U.S. sales of Boston Scientific's Taxus drug-coated stents fell nearly 30 percent to $175 million in the quarter. The decline came ahead of the launch of the company's next-generation Promus stent, which ...
Boston Scientific Q2 profit down15% hurt by charges, Sets Q3 Target - Update 22 Jul 2008 00:30 GMT
... Boston Scientific Q2 profit down15% hurt by charges, Sets ... return reserve in anticipation of its new drug-eluting stent platforms, while the 2007-second quarter results were ...
UPDATE 2-Boston Scientific net down 15 percent on charges 22 Jul 2008 00:05 GMT
... (Recasts, adds earnings details, analyst comments, byline) CHICAGO, July ... percent, hurt by declining sales of its drug-eluting stents to open clogged heart arteries and by ...
Earnings Decline at Boston Scientific 21 Jul 2008 23:30 GMT
... divested businesses added $19 million to the quarter's revenue. Worldwide sales of Boston Scientific's drug-coated coronary stent systems fell to $382 million during the quarter, down from $437 million a year ...

Boston Scientific Profit Falls 15% as Stent Sales Ease 21 Jul 2008 22:49 GMT
... On that basis, analysts on average had forecast a profit ... said worldwide sales of its drug-releasing heart stents declined to $382 million in the second ... million a year ago. U.S. sales of drug-eluting stents were $175 million, down from $249 ...
Boston Scientific second-quarter profit falls, hurt by one-time charges 21 Jul 2008 22:31 GMT
... quarter's revenue. Worldwide sales of Boston Scientific's drug-coated coronary stent systems fell to $382 million during the ... Vancouver to develop medical stents used in heart surgery. Stents are tiny tubes mesh tubes ...
Boston Sci earnings down in Q2 21 Jul 2008 22:30 GMT
... the med-tech company saw an uptick in cardiac-product sales. Natick, Mass.-based Boston Scientific (NYSE: BSX), ... from $2.07 billion. Sales of the company’s drug-coated coronary stents fell to $382 million, down from $437 ...
Boston Scientific posts lower 2nd - quarter profit, sales 21 Jul 2008 22:15 GMT
... divested businesses added $19 million to the quarter's revenue. Worldwide sales of Boston Scientific's drug-coated coronary stent systems fell to $382 million during the quarter, down from $437 million a year ...
Boston Scientific 2Q profit inches lower 21 Jul 2008 21:51 GMT
... divested businesses added $19 million to the quarter's revenue. Worldwide sales of Boston Scientific's drug-coated coronary stent systems fell to $382 million during the quarter, down from $437 million a year ...

Not satisfied with this news section? Make your own with the Newsletter Manager or try our other media monitoring services.

Boston Scientific Announces Results for Second Quarter Ended June 30, 2008 21 Jul 2008 21:30 GMT
... NATICK, Mass., July 21 /PRNewswire-FirstCall/ -- Boston Scientific Corporation ... FDA approval of our PROMUS(TM) Everolimus-Eluting Coronary Stent System, making us the only company to ... return reserve in anticipation of our new drug-eluting stent platforms, as compared to sales of ...
Isotechnika retains global rights to voclosporin 21 Jul 2008 19:58 GMT
... (Canada Newswire English Via Acquire Media NewsEdge) Attention Business/Health ... as the drug utilized in the CINATRA(TM) Drug Coated Coronary Stent system developed by the Company's partner, Atrium ...
PLC Systems Defers Pivotal Study of RenalGuard(TM) in the U.S. 21 Jul 2008 13:53 GMT
... Clinical study and limited launch in Italy continue FRANKLIN, ... procedures, such as those performed when placing drug-eluting stents. It is believed that allowing contrast media ...
PLC Systems Defers Pivotal Study of RenalGuard in the U.S. 21 Jul 2008 13:52 GMT
... Mark R. Tauscher, President and Chief Executive Officer of PLC, ... procedures, such as those performed when placing drug-eluting stents. It is believed that allowing contrast media ...
PLC Systems Defers Pivotal Study of RenalGuard in the U.S. 21 Jul 2008 13:52 GMT
... Mark R. Tauscher, President and Chief Executive Officer of PLC, ... procedures, such as those performed when placing drug-eluting stents. It is believed that allowing contrast media ...
PLC Systems Defers Pivotal Study of RenalGuard(TM) in the U.S. 21 Jul 2008 13:35 GMT
... PLC Systems Defers Pivotal Study of RenalGuard(TM) in the ... procedures, such as those performed when placing drug-eluting stents. It is believed that allowing contrast media ...
MCVI's 'bioactive' stent could speed recovery 21 Jul 2008 08:07 GMT
... is working to develop a revolutionary ''bioactive'' stent using biotech and genetic engineering. The firm ... on the market, including those that were drug-coated, might increase the risk of heart attacks. ''This project of the bioactive stent ...